GW Henssler & Associates Ltd. Grows Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• GW Henssler & Associates Ltd. increased its stake in Thermo Fisher Scientific by 110.7% during the first quarter, owning 36,710 shares valued at approximately $18.27 million.
• Several institutional investors, including GAMMA Investing LLC and Nuveen LLC, significantly increased their holdings in Thermo Fisher Scientific, with GAMMA's position rising by an astounding 60,610.9%.
• Analysts have issued varied price targets, with a consensus rating of "Moderate Buy" and an average price target of $593.00 for Thermo Fisher Scientific stock.

GW Henssler & Associates Ltd. raised its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 110.7% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 36,710 shares of the medical research company's stock after purchasing an additional 19,285 shares during the period. GW Henssler & Associates Ltd.'s holdings in Thermo Fisher Scientific were worth $18,267,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in TMO. GAMMA Investing LLC raised its position in Thermo Fisher Scientific by 60,610.9% during the first quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock valued at $1,203,859,000 after purchasing an additional 2,415,346 shares in the last quarter. Nuveen LLC bought a new position in shares of Thermo Fisher Scientific during the first quarter valued at about $532,360,000. Farallon Capital Management LLC grew its stake in shares of Thermo Fisher Scientific by 73.8% during the fourth quarter. Farallon Capital Management LLC now owns 1,233,256 shares of the medical research company's stock valued at $641,577,000 after buying an additional 523,800 shares during the last quarter. Sarasin & Partners LLP bought a new position in shares of Thermo Fisher Scientific during the first quarter valued at about $242,991,000. Finally, Two Sigma Advisers LP grew its stake in shares of Thermo Fisher Scientific by 81.6% during the fourth quarter. Two Sigma Advisers LP now owns 933,200 shares of the medical research company's stock valued at $485,479,000 after buying an additional 419,200 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at $57,697,567.04. The trade was a 7.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,896 shares of company stock valued at $13,603,438. 0.33% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on TMO shares. Raymond James Financial reaffirmed an "outperform" rating and set a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Robert W. Baird raised their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. UBS Group raised their price objective on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research note on Thursday, July 24th. Evercore ISI reduced their price objective on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Finally, HSBC reissued a "hold" rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and an average price target of $593.00.

Thermo Fisher Scientific Price Performance

TMO stock opened at $493.05 on Monday. The firm has a 50 day moving average price of $452.50 and a 200-day moving average price of $453.78. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88. The firm has a market capitalization of $186.18 billion, a price-to-earnings ratio of 28.52, a PEG ratio of 2.63 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same period last year, the business earned $5.37 earnings per share. The business's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's payout ratio is presently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.